MaRS Innovation

Federal and Provincial Proof of Principle Programs Support Translational Technology Development

Susanne Staer — Mon, 16 Aug 2010 13:40:03 +0000

TORONTO (August 16, 2010) – MaRS Innovation (MI) is pleased to announce that translational funding to support product development for early stage technologies from its Member Institutions has been successfully deployed from federal and provincial sources. At the federal level, three of MI’s commercialization projects have recently received notification of funding from the Canadian Institutes of Health Research (CIHR) Proof of Principle (PoP) program, amounting to approximately $470,000. Moreover, MI has successfully deployed about $1 million in proof of principle funding received from the Ontario Ministry of Research and Innovation (MRI) through the Ontario Centres of Excellence (OCE). This provincial program was previously managed by the MaRS Innovation founding commercialization partners in the life and physical sciences, BioDiscovery Toronto (BDT) and Technology Transfer Toronto (TTT). MaRS Innovation is grateful that these organizations laid the foundation for provincial proof of principle funding and looks forward to continuing a successful provincial PoP program.

MaRS Innovation establishes co-managed fund with Johnson & Johnson

Susanne Staer — Mon, 09 Aug 2010 13:07:06 +0000

TORONTO (August 9, 2010) – MaRS Innovation (MI) has signed a co-funding agreement with the Johnson & Johnson Corporate Office of Science and Technology to capitalize and accelerate the use of Toronto-based life-sciences technologies during the early stages of pharmaceutical and medical device development. The Translational Innovation Partnership Program (TIPP) is the first co-funding agreement of its kind for MI.

MaRS Innovation and Sunnybrook Health Sciences Centre Partner to Develop Four Exciting Medical Discoveries

Aaron Adams — Tue, 23 Mar 2010 04:00:43 +0000

TORONTO (March 23, 2010) — MaRS Innovation and Sunnybrook Health Sciences Centre have entered into their first set of agreements… Read More »

CIHR Commercialization Program funds insulin-alternative stem cell technology and nicotine addiction drug therapy

Aaron Adams — Tue, 02 Mar 2010 23:19:29 +0000

TORONTO (March 2, 2010) — MaRS Innovation is delighted to announce that two of its commercialization projects — notably an… Read More »

Leading-edge therapy targets brain chemistry of addiction

Aaron Adams — Thu, 17 Dec 2009 23:22:21 +0000

TORONTO (Dec. 17, 2009) — Grappling with nicotine addiction is never easy, but a new drug therapy — developed by Dr. Fang… Read More »

MaRS Innovation and CDRD Announce Strategic Collaboration

Aaron Adams — Mon, 30 Nov 2009 23:20:18 +0000

TORONTO, ON and VANCOUVER, BC (November 30, 2009) — MaRS Innovation and the Centre for Drug Research and Development (CDRD) are… Read More »

Physicist pairs with pharmaceutical scientist to design nano-particles for cancer imaging

Aaron Adams — Thu, 19 Nov 2009 23:21:53 +0000

TORONTO (November 19, 2009) — In the drive to improve early detection and treatment of cancer, a pair of Toronto scientists… Read More »

MaRS Innovation selects Diabetic Wound Healing Technology from The University of Toronto as its second commercialization opportunity

Aaron Adams — Tue, 30 Jun 2009 23:22:05 +0000

TORONTO (June 30, 2009) — MaRS Innovation and The University of Toronto (U of T) are pleased to announce that they… Read More »

MaRS Innovation selects umbilical cord stem cell technology from Samuel Lunenfeld Research Institute of Mount Sinai Hospital as its first commercialization opportunity

Aaron Adams — Mon, 29 Jun 2009 23:21:30 +0000

TORONTO (June 29, 2009) — MaRS Innovation and the Samuel Lunenfeld Research Institute of Mount Sinai Hospital are pleased to announce… Read More »